<DOC>
	<DOCNO>NCT01566552</DOCNO>
	<brief_summary>The study design determine use deliver point care , rapid diagnosis rK39 treatment AmBisome single dose 10 mg/kg administrate Primary Health Center ( PHC ) settings regard operational feasibility , safety final cure rate 6 month end treatment . Point care diagnosis treatment ( PCDT ) PHC level would bring best available intervention closer patient visceral leishmaniasis ( VL ) whose village within several kilometer PHC . This would support VL elimination program Indian subcontinent .</brief_summary>
	<brief_title>Single Dose Liposomal Amphotericin B Visceral Leishmaniasis</brief_title>
	<detailed_description>Primary Objectives : To evaluate operational feasibility deliver point care , rapid diagnosis rK39 treatment AmBisome® single dose 10 mg/kg , administrate Primary Health Centers ( PHC ) set regard feasibility safety . Secondary objective : To determine efficacy treatment scheme deliver district hospital PHC facility Methodology : Three district , Saran , Simastipur Muzaffarpur VL endemic state Bihar India select study . Initially , 300 eligible patient diagnose treated hospital level liposomal amphotericin B , use single dose 10 mg/kg . If significant feasibility safety issue identify group patient , 1000 additional subject diagnose treated PHC level . Feasibility determine proportion patient attend PHCs treat single dose AmBisome proportion patient need refer district hospital management adverse event . The initial cure rate determine day 30 , end treatment ( EOT ) . If initial cure observe , patient follow evaluated 6 month end treatment final clinical cure . Study medication , dose mode administration Liposomal Amphotericin B ( Gilead Sciences , Foster City , CA , USA ) formulate lyophilized powder reconstitute 10 ml distil water solution total dose dilute three time volume 5 % dextrose solution . Total infusion do 2 hour . Before infusion AmBisome® , patient give Paracetamol ( Adult : 500 mg ; Children 12 year 10 mg/kg ) Chlorpheniramine ( Adult : 4mg ; Children 12 year 1-2mg ) Parameters evaluation Laboratory parameter safety Adverse event Endpoints ( Feasibility ) - 85 % VL patient attend PHCs treat single dose AmBisome scheme . - 3 % patient treat single dose AmBisome refer district hospital AEs management . - 95 % patient treat single dose AmBisome cure 6 month EOT . Endpoints ( Efficacy ) Initial Cure : Defined remission fever , decrease spleen size compare baseline , hemoglobin increase least 10 % compare baseline least 10g/dl , improvement clinical sign symptom day 30 . Final Cure : Defined fulfillment follow criterion 6 month EOT : No relapse initial cure , absence fever increase spleen size compare day 30 hemoglobin increase least10 % compare day 30 least 10g/dl . Statistical method Efficacy analysis : Calculation cure rate 95 % 90 % low confidence limit accord Clopper Pearson method . Safety analysis : Calculation overall incidence adverse event .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>1 . Male female patient ≥ 5 year age 2 . History fever 2 week 3 . Splenomegaly 4. rK 39 rapid test positive 5 . Biochemical hematological test value follow : Hemoglobin ≥ 5 g/dl White blood cell count ≥1.0 x 109/L AST , ALT ≤ 3 time upper limit normal Serum creatinine level within normal limit 6 . Written inform consent patient/ parent guardian 18 year old . 1 . A history intercurrent presence clinical sign / symptom concurrent disease / condition ( e.g . Chronic alcohol consumption drug addiction , renal , hepatic , cardiovascular CNS disease ; diabetes mellitus , dehydration , infectious disease major psychiatric disease ) intercurrent condition control start treatment AmBisome . 2 . Any condition accord investigator might prevent patient complete study therapy subsequent follow 3 . A history allergy hypersensitivity Amphotericin B 4 . Previous treatment VL 5 . Prior treatment failure Amphotericin B 6 . Post Kalaazar Dermal Leishmaniasis ( PKDL</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AMBISOME</keyword>
	<keyword>VISCERAL LEISHMANIASIS</keyword>
	<keyword>SINGLE DOSE</keyword>
</DOC>